Compare ENTA & SUUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTA | SUUN |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 59.0M |
| IPO Year | 2013 | N/A |
| Metric | ENTA | SUUN |
|---|---|---|
| Price | $14.71 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $20.40 | $5.00 |
| AVG Volume (30 Days) | 288.3K | ★ 496.4K |
| Earning Date | 11-17-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,324,000.00 | $32,753,484.00 |
| Revenue This Year | $0.99 | $127.67 |
| Revenue Next Year | $0.19 | $4.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.09 | $1.23 |
| 52 Week High | $15.34 | $6.43 |
| Indicator | ENTA | SUUN |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 44.94 |
| Support Level | $13.75 | $1.56 |
| Resistance Level | $14.79 | $1.72 |
| Average True Range (ATR) | 0.74 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 90.89 | 21.02 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
SolarBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.